OrbiMed’s Allergan plc AGN Stock Holding History

OrbiMed’s Portfolio AGN Stock Details AGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-50,000	Closed	-$11.5M	–	144
2016 Q3	$11.5M	Sell	50,000 -100,000	-67%	-$24.4M	0.13%	96
2016 Q2	$34.7M	Buy	150,000 +50,000	+50%	+$11.5M	0.36%	60
2016 Q1	$26.8M	Buy	+100,000	New	+$28.6M	0.28%	62
2015 Q3	–	Sell	-25,000	Closed	-$7.59M	–	143
2015 Q2	$7.59M	Sell	25,000 -475,000	-95%	-$142M	0.06%	113
2015 Q1	$149M	Buy	+500,000	New	+$143M	1.27%	28
2013 Q4	–	Sell	-150,000	Closed	-$21.6M	–	139
2013 Q3	$21.6M	Buy	150,000 +9,300	+7%	+$1.24M	0.39%	54
2013 Q2	$17.8M	Buy	+140,700	New	+$15.9M	0.38%	55

Other funds holding AGN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Longview Partners St Peter Port, Guernsey $7.06B AUM 3.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

OrbiMed's AGN Position: Q1 2019 in Review

OrbiMed sold out of Allergan plc (AGN) in Q1 2019, closing a stake of 957,000 shares — an estimated $128M sold.

OrbiMed first reported a position in AGN in Q2 2013 and held it in 23 quarters. The position peaked at $470M in Q1 2015. 991 funds tracked by Wall St. Rank hold AGN as of Q1 2019.

OrbiMed reported no remaining Allergan plc position as of Q1 2019 after selling out during the quarter.
OrbiMed sold 957,000 Allergan plc shares in Q1 2019, an estimated $128M.
OrbiMed first reported a position in Allergan plc in Q2 2013 and held it in 23 quarters.
OrbiMed's Allergan plc position peaked at $470M in Q1 2015.
991 funds tracked by Wall St. Rank held Allergan plc as of Q1 2019.

Based on OrbiMed's 13F filing for Q1 2019, filed 15 May 2019.